All News

The review comes amid growing attention directed at identifying treatments that can prevent progression of polycythemia vera (PV) to myelofibrosis or an aggressive form of acute myeloid leukemia.

Ilumya (tildrakizumab) was shown to be safe and effective in controlling moderate to severe psoriasis for adults through 5 years of treatment in a recent study.

Students attending middle school and high school exhibited significantly improved sleep duration and daytime sleepiness with later school start times, while elementary school students were shown to be minimally affected by earlier start times.

Elevated levels of 2 inflammatory biomarkers may indicate a greater heart failure hospitalization risk for patients who have diagnosed atrial fibrillation.

The in vitro study of melanoma cells analyzed the molecular mechanisms of the pair of proteasome inhibitors, finding that they reduced B16-F1 tumor growth.

Karen Coderre, PharmD, and Madhavi Manduru-Rao, PharmD, detail how CMS' increased weighting for Consumer Assessment of Health Care Providers and Systems surveys impacts Star ratings.

The pandemic reduced visits to specialists last year, which in turn reduced the volume of prescriptions, according to a presentation at the Academy of Managed Care Pharmacy 2021 meeting.

A new study finds high rates of suicide among female nurses in the United States; President Joe Biden aims to undo Trump-era restrictions on abortion referrals; research indicates regular exercise may prevent severe COVID-19 outcomes.

This is a case study of a male patient with Fabry disease who presented with severe anaphylaxis following re-initiation of full-strength treatment with intravenous agalsidase beta (Fabrazyme).

New research presented at AMCP 2021, the annual meeting of the Academy of Managed Care Pharmacy, evaluated treatment patterns and costs related to hospitalization for patients with pulmonary arterial hypertension (PAH).

The CDC's Advisory Committee on Immunization Practices (ACIP) declined to change the current recommendation to pause administration of Johnson & Johnson's COVID-19 vaccine.

Compared with when Medicare Part D launched, therapies today are more expensive. A panel at the Academy of Managed Care Pharmacy 2021 meeting discussed how the benefit needs to adapt to keep up with the future.

For some living with HIV, old wounds have reopened during the COVID-19 pandemic, explained Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health and director of the Center for Health, Identity, Behavior and Prevention Studies.

Brenden O’Hara, RPh, BCACP, from Blue Cross Blue Shield of North Carolina, talked about the pharmacist’s role in improving outcomes in value-based contracts and why collaboration is needed.

A report by the Harvard Business Review found a significant gap between employee needs and employer benefit offerings for treatment of physical and emotional pain, with a holistic approach associated with savings of 50% on medical claims for back and joint care.

Moderna announces upcoming trial of a vaccine candidate against flu; April 11-17 marks Black Maternal Health Week; the European Commission will not renew COVID-19 vaccine contracts with Johnson & Johnson and AstraZeneca when they expire next year.

Higher oxygen saturation targets are linked with greater progression in some cases of retinopathy of prematurity (ROP), but the incidence remains stable.

PIE, or a preapproval information exchange, is aimed at streamlining payer and health plan involvement so that it happens at the same time a drug developer submits an application to the FDA, instead of after a drug is approved, with the intent of speeding patient access to therapies.

Results of a questionnaire-based study show higher body mass index (BMI) is associated with worse migraine symptoms and comorbidities.

Neglecting public health in state budgets for more than 10 years created an environment that was ill-suited to deal with the challenges of COVID-19 as well as other issues. On this episode of Managed Care Cast, we speak with one of the authors of a recent paper that examined state funding trends from 2008 to 2018 and discuss what could be done in the future to avoid past mistakes.

A prospective bicentric cohort study among individuals with relapsing-remitting multiple sclerosis (RRMS) showed that 32% developed at least 1 skin-related adverse reaction following cladribine administration.

Christina Polomoff, PharmD, BCACP, BCGP, discusses the differences between manufacturer coupons and cash cards and how they financially affect health plans and pharmacies.

A better understanding of the genetic etiology of pulmonary arterial hypertension and its molecular variants is needed to develop better therapies for the disease, which has no agents available that can reverse or halt it.

After cases of rare and severe blood clots led to 1 death and 1 hospitalization, the CDC and FDA will pause the use of Johnson & Johnson's (J&J) COVID-19 vaccine.

A new study finds no link between the UK COVID-19 variant and more severe disease; study finds more than 1 in 10 US children with COVID-19 hospitalized; therapy setbacks in Huntington disease.

Jonathan Silverberg, MD, PhD, MPH, is an author of the poster, “Efficacy of Ruxolitinib Cream Among Patients With Atopic Dermatitis Based on Previous Medication History: Pooled Results From Two Phase 3 Studies,” which will be presented at this year’s American Academy of Dermatology Virtual Meeting Experience (AAD VMX).

Previous studies have investigated the association between hot flashes and immune system activation among women with HIV, but this is the first study to investigate an additional link to adverse subclinical cardiac pathology.

Several barriers continue to impede the transition to value-based payment, particularly administrative and clinical data connectivity, transparency of quality metrics and quality measures, and prioritization of social determinants of health.

Deficiencies in immunoglobulin levels frequently coexist with type 1 diabetes (T1D) in pediatric patients according to new study results.

Hospital reimbursement deals slow the adoption of biosimilars in oncology, but cost concerns contribute to the incentives to use these agents.